A multicenter randomized, double-blind placebo-controlled study of invigorating spleen and Clearing Lung in the treatment of bronchiectasis (spleen deficiency and lung heat syndrome)
- Conditions
- Bronchiectasis
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1.Outpatients meeting the diagnostic criteria for stable bronchiectasis; 2. Aged 18-70; 3. TCM syndrome differentiation is lung qi deficiency phlegm heat accumulation of lung; 4 patients with at least one exacerbation in the past 1 year; 5. Those who are willing to comply with the doctor's diagnosis and treatment arrangement and sign the informed consent.
1.With hemoptysis as the main manifestation of dry bronchioma patients; 2.Patients with pulmonary interstitial fibrosis resulting in tractive bronchiectasis; 3.Patients with active pulmonary tuberculosis and pulmonary fungal infection; 4.Pregnant women or lactating women; 5.History of chronic alcohol or substance abuse or any factors affecting compliance;6.Poor compliance during screening; 7.Complicated with primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; 8.abnormal liver and kidney function: liver (ALT or AST) more than twice the upper limit of normal value or abnormal kidney function (BUN or Cr); 9.mental patients; 10. allergic constitution and allergic to this drug; 11.Participated in other clinical trials within 1 month; 12.Other conditions that the investigator considers inappropriate for inclusion.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the Qualify of Life Questionnaire for Bronchiectasis;the number of exacerbations;
- Secondary Outcome Measures
Name Time Method neutrophil elastase;hepatic and renal function;TNF-a;TCM syndrome integral;IL-8;FEV1\FEV1%pred\FVC\FVC%pred\FEV1/FVC;intestinal flora;Th17;CD8+;NEUT%;CD4+;Treg17;IL-6;mMRC;